NCT04414748View on ClinicalTrials.gov

Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Patients Undergoing PGT-A

PHASE3CompletedINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

June 10, 2020

Primary Completion Date

December 1, 2024

Study Completion Date

May 27, 2025

Conditions
Preimplantation Genetic TestingProgestin-primed Ovarian StimulationEuploid RateGnRH Antagonist
Interventions
DRUG

GnRH antagonist

GnRH antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of COH till the day of the ovulation trigger

DRUG

oral Duphaston

oral Duphaston 10mg bd from Day 3 of COH till the day of ovulation trigger.

Trial Locations (1)

200011

Shanghai JiAi Genetics & IVF Institute, Shanghai

All Listed Sponsors
lead

ShangHai Ji Ai Genetics & IVF Institute

OTHER

NCT04414748 - Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Patients Undergoing PGT-A | Biotech Hunter | Biotech Hunter